Shared on05 Sep 25
With both the discount rate and future P/E remaining virtually unchanged, there is no notable shift in valuation drivers, resulting in the consensus analyst price target for Poly Medicure holding steady at ₹2277. What's in the News Poly Medicure incorporated a wholly owned step-down subsidiary, RisoR Holdings B.V., in Amsterdam, Netherlands, to acquire a 90% economic interest in the PendraCare Group via agreements with Welling Holdings B.V. Management confirmed strong liquidity (INR 12,490 million), supporting both organic and inorganic growth; active M&A strategy focused on technology acquisitions in core and adjacent medical verticals.
Shared on23 Apr 25Fair value Decreased 0.034%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 1.01%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 1.43%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on12 Mar 25Fair value Increased 0.27%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.